ECM1 and ovarian cancer: Therefore, we conclude that PS VII may hinder the binding of ECM1 to VEGFR2 and inhibit the FAK/AKT/GSK3β signaling pathway in PARP inhibitor-resistant ovarian cancer cells by activating RORα, affecting functions such as glycolysis and angiogenesis, and ultimately improving its resistance treatment.